Belimumab - An anti-BLyS human monoclonal antibody for rheumatoid arthritis

Expert Opinion on Biological Therapy

Volumn 13, Issue 2, 2013, Pages 315-322

  Jin, Xingzhong ^a,b   Ding, Changhai ^a,c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

autoimmune disease; B cell therapy; belimumab; BLyS inhibitor; LymphoStat B; rheumatoid arthritis

Indexed keywords

APRIL PROTEIN; BELIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FAS LIGAND; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 4; LYMPHOTOXIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COUGHING; DAS28; DIARRHEA; DISEASE ACTIVITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESCHERICHIA COLI; FATIGUE; HAPLORHINI; HUMAN; IC 50; INFECTION; JOINT SWELLING; LEG PAIN; MEMORY CELL; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SINUSITIS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS PNEUMONIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS;

EID: 84872191194     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.758248     Document Type: Article

References (30)

1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med 2007;120(11):936-9 (Pubitemid 47633476)
2. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5(7):564-76 (Pubitemid 43971191)
3. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-96
4. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010;70(5):529-40
5. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006;66(15):1933-48 (Pubitemid 44771932)
6. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48(6):1484-92 (Pubitemid 36682354)
7. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285(5425):260-3 (Pubitemid 29330000)
8. Cancro MP. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004;202:237-49 (Pubitemid 39576916)
9. Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006;7(5):464-72 .. This article is the first, best to the authors' knowledge, to review the preclinical and clinical development of belimumab for the treatment of autoimmune disease. (Pubitemid 43772987)
10. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64 (Pubitemid 37174532)
11. Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97(7):3370-4
12. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190(11):1697-710 (Pubitemid 30002351)
13. Moller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-Alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006;27(4):391-408 (Pubitemid 43825163)
14. Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 2006;1(3):193-200
15. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-Alpha antagonists. Medicine 2005;84(5):291-302 (Pubitemid 41368482)
16. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B. Drugs R D 2010;10(1):55-64 This article reviewed the development history and scientific profile of belimumab.
17. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48(11):3253-64 . This paper detailed the isolation of anti-BLyS antibodies and generation of belimumab.
18. Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012;30(1):69-77
19. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006;91(2):586-99 . This paper demonstrated the bioactivity and pharmacokinetics of belimumab in cynomolgus monkeys. (Pubitemid 43827311)
20. Cai W, Chen C, Zhong ZJ, et al. Bioavailability, pharmacokinetics, and safety of belimumab administered subcutaneously in healthy subjects. Arthritis Rheum 2012;64(S10):616
21. Stohl W, Chatham W, Weisman M, et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 2005;52:S444
22. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10(5):11
23. Furie R, Stohl W, Ginzler E, et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003;48:S377
24. McKay J, Chwalinska-Sadowska H, Boling E. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum 2005;52(9):S710-11 .. This 2005 meeting abstract reported results of a Phase II trials in patients with moderate and severe RA who received belimumab or placebo, along with standard of care.
25. Merrill JT, Wallace DJ, McKay J. Long-term safety profile of belimumab (fully human monoclonal antibody to BLyS) in patients with systematic lupus erythematosus (SLE). Ann Rheum Dis 2008;67(Suppl 2):217
26. Merrill JT, Furie RA, Wallace DJ, et al. Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(S10):584 .. This 2011 meeting abstract documented long-term (6 years) safety profile of belimumab for the treatment of SLE.
27. Genovese M, Filipowicz-Sosnowska A, Merrill JT. Differential responsiveness to belimumab in combination with standard of care therapy in RF+, TNF alpha-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. Arthritis Rheum 2005;52(9):S738 .. This abstract reported the efficacy of belimumab in RA patients subgroups who were baseline RF positive, anti-TNF naive and those who had failed methotrexate therapy before. 28. St Clair EW, Tedder TF. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum 2006;54(1):1-9
28. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81 (Pubitemid 38758544)
29. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-Activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66(5):700-3 (Pubitemid 46707145)
30. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8(6):R167